Clinical Trial

E5202: FOLFOX vs. FOLFOX plus Avastin (bevacizumab) for patients who have undergone resection of stage II CRC
 

This study is for patients with stage II colon cancer who have undergone resection without evidence of metastatic disease, who are thinking about  post-operative chemotherapy (adjuvant therapy)
 
Protocol number: E5202

Type of cancer: Stage II Colorectal Cancer

Phase number: III

Summary:  This is a phase III study for patients who need adjuvant chemotherapy after surgery.  Patients should have Stage II colon cancer. The study compares the effectiveness of standard treatment (FOLFOX) to the effectiveness of FOLFOX plus bevacizumab (Avastin), which is a monoclonal antibody that is thought to block the growth of some cancer cells. 

 
 
Contact

Contact Carole Stromberg, RN: cstromb1@jhmi.edu
Phone: 410-502-7171   

 
Return to Clinical Trials